REG - Trellus Health PLC - Contract Signed with Leading Global CRO

Trellus HealthAnnouncement

22/10/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20251022:nRSV2931Ea&default-theme=true

RNS Number : 2931E  Trellus Health PLC  22 October 2025

Trellus Health plc

("Trellus Health", the "Company" or the "Group")

 

Contract Signed with Leading Global CRO

 

LONDON, U.K. AND NEW YORK, U.S. (22 October 2025). Trellus Health® plc (AIM:
TRLS), a healthcare company delivering Trellus Elevate®, a digital platform
that integrates data analytics with personalised, scientifically proven
resilience programs and value-based solutions to manage complex chronic
conditions, announces that, further to yesterday's announcement that it is in
late stage contracting discussions, it has signed a 12 month contract (the
"Contract") with one of the largest global Clinical Research Organisations
(CROs), to support recruitment and enrolment optimisation for an ongoing
mid-stage clinical trial in the field of immunology and inflammation. The
Contract is due to commence later this year.

 

The clinical trials sector remains a strategic growth area for the Group and,
accordingly, the Company has launched Trellus TrialSet™. This program is
designed to support potential clinical trial participants by identifying
individuals with low resilience, who may be hesitant to enrol in the trial,
and provide structured services to strengthen their readiness.

 

By leveraging the Company's proprietary resilience methodology alongside
behavioural science, tailored education, and personalised engagement, Trellus
TrialSet™ enables participants to move from uncertainty to confidence,
ensuring they are prepared to successfully enter and remain in the trial. This
is expected to enhance recruitment efficiency, improve retention, and deliver
cost savings for partners. The Contract, which includes an upfront fee, a
monthly management fee, and milestone payments, is structured around three key
performance indicators: (i) the number of potential eligible participants
opting into the Trellus TrialSet™ programme, (ii) the increase in qualified
participants referred for screening, and (iii) the reduction in the screen
failure rate.

 

As further announced yesterday, Trellus Health® has also now been granted
preferred vendor status ("Preferred Vendor Status") by a second leading global
contract research organisation (CRO) and negotiations continue to support
recruitment for an additional clinical program. Whilst the granting of
Preferred Vendor Status is not revenue generating in itself, it reinforces the
strength and differentiation of Trellus Health's offering in the clinical
trials vertical and provides direct access to the CRO's client base as well as
accelerating procurement and contracting timelines.

 

Dr. Marla Dubinsky, Chief Executive Officer of Trellus Health, said: "Clinical
trials continue to face challenges in recruitment, retention and study
completion. We are proud to launch Trellus TrialSet™ to directly address
these issues by proactively assessing and preparing participants, ensuring
only those who are ready will enter the trial. This resilience-based approach
is designed to significantly reduce screen failures and dropouts while
delivering meaningful cost savings for our partners.

 

We are pleased to announce this partnership with a leading global CRO. While
it does not immediately extend the Company's current cash runway beyond early
December, it reflects our ability to secure contracts with leading CROs and
represents an important step in building commercial traction. In addition, our
designation as a preferred vendor by a second leading CRO for supporting
recruitment for an additional clinical trial program further strengthens our
position in the clinical trial vertical.

We will provide further updates in due course, as appropriate."

Regulatory Information

This announcement contains inside information for the purposes of article 7 of
the Market Abuse Regulation (EU) 596/2014 as amended by regulation 11 of the
Market Abuse (Amendment) (EU Exit) Regulations 2019/310.  Upon the
publication of this announcement, this inside information is now considered to
be in the public domain.

 

Enquiries:

 

 Trellus Health plc                                                     https://trellushealth.com/ (https://trellushealth.com/)

 Dr. Marla Dubinsky, Chief Executive Officer and Co-Founder            Via Walbrook PR
 Joy Bessenger, Chief Financial Officer

 Singer Capital Markets
 Jen Boorer / James Todd / Patrick Weaver                              Tel: +44 (0)20 7496 3000

 Walbrook PR           Tel: +44 (0)20 7933 8780 or trellus@walbrookpr.com
                       (mailto:trellus@walbrookpr.com)
 Paul McManus / Lianne Applegarth /          Mob: +44 (0)7980 541 893 / +44 (0)7584 391 303/
 Alice Woodings                                                        +44 (0)7407 804 654

 

 

 

 

About Trellus Health plc (www.trellushealth.com)

Trellus Health® (AIM: TRLS) is a healthcare company providing value-based
innovative solutions and services, helping people with chronic conditions take
control of their health through a proven, scientifically validated
self-management solution and continuous, personalised support. Trellus
Health's approach empowers patients to better navigate the emotional and
physical challenges of their conditions, leading to significant cost savings,
enhanced treatment adherence, and long-term, sustainable health outcomes.

Trellus Health® integrates its proprietary resilience-based methodology with
the technology, tools, and expert coaching and educator team to deliver
Trellus Elevate®, a whole-person technology-enhanced condition management
platform. The Company is initially focusing on chronic costly GI conditions
that have a high mental health burden, such as Inflammatory Bowel Disease
(IBD). Among IBD patients, applying the Trellus Elevate® methodology resulted
in over 90% fewer hospitalisations and a reduction of over 70% in emergency
room visits. Given the common emotional and mental health struggles associated
with a variety of chronic conditions and therapeutic areas, Trellus Health®
considers its approach to have potential utility and demand across many
conditions.

The Company also offers Trellus TrialSet™, a solution for pharmaceutical
partners spanning clinical trials to commercialisation, applying the same
validated resilience science and platform to support trial success and
long-term patient engagement

 

The Company was founded by Icahn School of Medicine at Mount Sinai faculty
members Marla C. Dubinsky, MD, and Laurie Keefer, PhD, both world-leading
experts in treating both the physical and emotional impacts of IBD, with a
combined 50 years of pioneering whole-person healthcare innovation.

 

Shares in Trellus Health were admitted to trading on AIM in May 2021, under
the ticker TRLS. For more information, visit: www.trellushealth.com
(http://www.trellushealth.com)

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  CNTPPGQGUUPAPUG



            Copyright 2019 Regulatory News Service, all rights reserved